Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study
Clinical Scorecard: Effectiveness and Safety of Paclitaxel-Coated Balloon Angioplasty for Coronary Small Vessel Disease: A Prospective, Multicenter, Randomized Clinical Study
At a Glance
Category
Detail
Condition
Coronary Small Vessel Disease (SVD) and Very Small Vessel Disease (VSVD)
Key Mechanisms
Paclitaxel-coated balloons are used to reduce in-lesion late lumen loss and improve safety outcomes compared to drug-eluting stents.
Target Population
Patients aged 18-75 with stable or unstable angina, NSTEMI, or STEMI beyond 1 week, having de novo coronary small or very small vessel lesions.
Care Setting
Multicenter, prospective, randomized controlled trial across eight hospitals.
Key Highlights
DCB shows lower in-lesion late lumen loss compared to everolimus-eluting stents in SVD.
DCB is increasingly recommended for patients with SVD and VSVD.
Patients with VSVD tend to have more severe symptoms and poorer prognosis.
Guideline-Based Recommendations
Diagnosis
Interventional treatment is recommended for patients with SVD presenting with ischemic symptoms.
Management
Paclitaxel-coated balloons are a viable treatment option for SVD and VSVD.
Monitoring & Follow-up
Evaluate in-lesion late lumen loss and other endpoints at 9 months post-procedure.
Risks
Higher rates of in-stent thrombosis and myocardial infarction observed with drug-eluting stents.
Patient & Prescribing Data
Patients with RVD between ≥ 1.50 mm and ≤ 2.50 mm.
Successful predilatation of a single target lesion is required for enrollment.
Clinical Best Practices
Adhere to CONSORT guidelines for clinical trials.
Ensure independent review of angiographic data to minimize bias.
Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.
A consensus statement called for immediate adoption of enhanced radiation protection devices, although evidence of long-term health benefits and effectiveness across procedural settings remains limited.
